2 November 2026

Osteopore strengthens focus on Orthopaedic business in Singapore through direct selling

Highlights

- **Osteopore's subsidiary, Osteopore International Pte Ltd and DKSH Singapore Pte Ltd ("DKSH") have agreed to conclude the exclusive contract sales and marketing arrangement for Osteopore's Orthopaedic products in Singapore with effect from 31 December 2026, ahead of its scheduled expiry.**
- **Osteopore International will assume the sales and marketing of the business effectively from 1 January 2027.**
- **This strengthens focus for the Orthopaedic business in its home market Singapore, streamlining and enhancing customer interaction and experience, especially since the establishment of Osteopore's 3D printing services and the introduction of the injectable regenerative bone fillers targeting the same customer group, as announced on 10 February 2026 [1].**

Australian-Singaporean regenerative medicine company **Osteopore Limited** (**ASX: OSX**; **Osteopore** or **Company**) – a global leader in 3D-printed biomimetic and bioresorbable implants – announces that its subsidiary, Osteopore International Pte Ltd and DKSH Singapore Pte Ltd ("DKSH") have agreed to conclude the exclusive contract sales and marketing agreement for its Orthopaedic products in Singapore with effect from 31 December 2026, ahead of its scheduled expiry. Following an agreed transition period, Osteopore International will assume responsibilities for the sales and marketing of the business in Singapore effectively from 1 January 2027.

[1] ASX announcement, "OSX establishes new business in 3D printing services", 10 February 2026.

On 6 November 2024[2], Osteopore International announced the signing of a 5-year exclusive multi-year contract sales and marketing agreement with DKSH Singapore Pte. Ltd., to promote the Company's off-the-shelf products for bone loss treatment in upper and lower extremities.

With the support of DKSH, Osteopore's products have gained adoption in a number of Singapore's hospitals and clinics – Osteopore would like to thank DKSH and its team for their support over the past 2 years.

This initiative to directly manage the business comes from the need to strengthen focus for the Orthopaedic business in Singapore, streamlining and enhancing customer interaction and experience. This is particularly important now with the establishment of Osteopore's 3D printing services as announced on 10 February 2026 [1], and the upcoming introduction of the injectable regenerative bone filler [3], both of which target the same customer group.

Over the past 2 years, Osteopore's Orthopaedic products have been deployed in all major Singapore public hospitals. In addition, the product has also been adopted by orthopaedic surgeons who offer surgical treatment for knee preservation and bone reconstruction (in cases of substantial bone loss).

Osteopore has recently strengthened its sales and marketing team, and is now well-positioned to support the business and its customers in Singapore.

[2] ASX announcement, "Osteopore inks DKSH deal to sell ortho products in Singapore", 6 November 2024.

[3] ASX announcement, "OSX signs agreement for injectable regenerative bone filler", 12 March 2026.

Commenting on the initiative to manage the business directly in Singapore, CEO Dr Yujing Lim, said:

"We would like to thank DKSH for its support over the past 2 years. Singapore is a key market to us as it is our home-market, one where direct customer interaction drives adoption and innovation.

"We have reached an important phase in the growth of our Orthopaedic business in Singapore – one that requires focus and dedicated resources to cultivate and grow further.

"With the launch of the 3D printing services, as well as the upcoming launch of the injectable regenerative bone filler targeting the same customers, this direct approach strengthens customer communication and experience", said Dr Lim.

ENDS

This announcement has been authorised for release to the ASX by the Board of Osteopore Limited.

For more information, please contact:

Dr Yujing Lim
Chief Executive Officer
Osteopore Limited
E: lim_yujing@osteopore.com

Mark Leong
Executive Chairman
Osteopore Limited
E: mark_leong@osteopore.com

About Osteopore Limited

Osteopore Ltd. is a global medical technology company founded in Singapore and listed in Australia that commercialises products designed to enable natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolves over time to only allow natural and healthy bone tissue, significantly reducing the post-surgery complications commonly associated with permanent bone implants. Our 3D printing technology is unique to Osteopore.